PLACENTEX SOL CUT 10F

PLACENTEX 0,75 MG/3 ML EDUCATION

active ingredients

1 vial of 3 ml contains: Active Principle: Polydesossiribonucleotide 0.75 mg For full list of excipients, see paragraph 6.1

Excellent

PLACENTEX 0,75 mg/3 ml skin solution: sodium chloride; water for injectable preparations.

Therapeutic indications

Connective pathologies on a distrophic or distrophic-ulcerative basis: scarring, antidistrophic.

Contraindications

Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1.

Population

Local applications 1 or 2 times a day, imbibendo sterile garzes or according to medical evaluation.

Conservation

This medicine does not require any special precaution for conservation. Store Placentex away from heat sources and protected from light.

Warnings

It is possible the occurrence of hypersensitivity phenomena to the components, which require the suspension of administration. Desensitizing medical therapy may be necessary.

Interactions

Interaction studies have not been carried out.

Effects

Hypersensitivity reactions have been reported (see paragraph 4.4). Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazionireazioni-avverse.

Overdosing

No overdose cases have been reported.

Data concerning the use of Placentex in pregnant women do not exist or are in limited number.

Source: Farmadati